5 stories mentioning CORUpdated 24d ago
Every FINWIRES story that references COR, newest first.
Dermot Mark Durcan, Director, on May 28, 2026, executed a purchase for 4,000 shares in Cencora (COR) for $1,065,040. Following the Form 4 filing with the SEC, Durcan has control over a total of 27,767 common shares of the company, with 27,767 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1140859/000120235826000004/xslF345X05/wk-form4_1779999812.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target by $86 to $300, a 16.9x multiple of our FY 26 (Sep.) EPS estimate of $17.73 (up from $17.55; our FY 27 estimate is raised to $19.67 from $19.58), between COR's three- and five-year historical forward averages of 17.4x and 15.8x, respectively. Shares declined significantly following a Q2 revenue miss (3.3% below consensus), impacted by customer losses and manufacturer list price reductions, causing a cut to annual sales growth guidance to 5% from 8%. Positively, the International Healthcare segment's revenue grew 13% (7% in constant currency) and operating income increased 14% (13% in constant currency), supported by a rebound in the global specialty logistics business, which achieved its second straight quarter of operating income growth. We look favorably on COR raising FY 26 adjusted operating income growth guidance (13% midpoint vs. 12.5%) as well as adjusted EPS guidance ($17.65-$17.90 from $17.45-$17.75 previously), supported by the resumption of share repurchases ($1B by year-end).
McKesson's (MCK) fiscal 2027 guidance is "encouraging," and its commentary on biosimilars should help ease recent pressure on drug distributors, Morgan Stanley said in a Friday note.The investment firm said McKesson's targets and underlying assumptions support their bullish outlook on distributors that continue to benefit from structural tailwinds.On Cencora (COR), the brokerage said the company faces idiosyncratic contract dynamics with Express Scripts that could lead to continued insourcing of biosimilar specialty drugs and add an overhang to the stock. The recent pullback in Cencora shares was overdone, according to the note.Morgan Stanley raised their fiscal 2026 adjusted earnings estimate on Cencora to $17.76 from $17.63. Analysts surveyed by FactSet expect $17.73.Morgan Stanley has an overweight rating and a $966 price target on McKesson.The firm reiterated its overweight rating on Cencora and lowered its price target to $342 from $400.Price: $265.08, Change: $+9.42, Percent Change: +3.68%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Cencora delivered solid Q2 FY 26 results with adjusted EPS of $4.75 (+7.5% Y/Y), beating consensus by $0.02. Revenue growth of 3.8% to $78.4B represented a deceleration from recent quarterly trends. U.S. Healthcare Solutions (88% of revenue) posted 2.9% growth to $68.8B driven by specialty product volumes, GLP-1 class drug sales, and contributions from the OneOncology acquisition, with operating margin expanding to 1.45% from 1.41%, while International Healthcare Solutions showed strong 13.0% growth (7.2% constant currency) to $7.6B primarily from European distribution business expansion with margin improvement to 2.32%. COR raised full-year adjusted EPS guidance to $17.65-$17.90 from $17.45-$17.75, supported by resumption of share repurchases targeting $1B by year-end. We view the guidance raise and accelerated capital returns positively. COR maintained adjusted FCF guidance of approximately $3.0B for FY 26, supporting continued dividend growth and capital returns to shareholders in our view.
Cencora (COR) has an average rating of overweight and mean price target of $405.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
